BB Biotech AG
BBZA.DE
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.94B
Close$
$1.80
96.6% downside
Current Fair Value
96.6% downsideOvervalued by 96.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.94 Billion |
|---|---|
| Enterprise Value | $4.74 Billion |
| Dividend Yield | $2.43 (4.58%) |
| Earnings per Share | $10.54 |
| Beta | 0.64 |
| Outstanding Shares | 59,738,662 |
Return
| Return on Equity | 43.74% |
|---|---|
| Return on Assets | 43.66% |
| Return on Invested Capital | 43.67% |
Valuation & Multiples
| P/E Ratio | 2.01 |
|---|---|
| PEG | -0.36 |
| Price to Sales | 26.55 |
| Price to Book Ratio | 1.04 |
| Enterprise Value to Revenue | 32.46 |
| Enterprise Value to EBIT | 3.51 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 23, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BB Biotech AG
10 employees
CEO: Daniel Koller BB Biotech AG provides investment services for biotechnology sector. It invests in portfolio of companies that are engaged in developing and marketing of innovative biotech drugs. It offers investors a exposure to a focused portfolio of ...